Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)’s stock price has increased by 54.61 compared to its previous closing price of 1.73. However, the company has seen a 40.90% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-25 that The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ — Galmed Pharmaceuticals Ltd.
Is It Worth Investing in Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Right Now?
Additionally, the 36-month beta value for GLMD is 0.63. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GLMD is 1.63M and currently, short sellers hold a 0.30% ratio of that float. The average trading volume of GLMD on March 17, 2025 was 32.65K shares.
GLMD’s Market Performance
GLMD stock saw an increase of 40.90% in the past week, with a monthly gain of 5.95% and a quarterly increase of -7.29%. The volatility ratio for the week is 10.43%, and the volatility levels for the last 30 days are 10.16% for Galmed Pharmaceuticals Ltd (GLMD). The simple moving average for the last 20 days is 22.61% for GLMD stock, with a simple moving average of -25.08% for the last 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at 4.18% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.78% of loss for the given period.
Volatility was left at 10.16%, however, over the last 30 days, the volatility rate increased by 10.43%, as shares surge +0.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.74% lower at present.
During the last 5 trading sessions, GLMD rose by +38.47%, which changed the moving average for the period of 200-days by -41.08% in comparison to the 20-day moving average, which settled at $2.1754. In addition, Galmed Pharmaceuticals Ltd saw -16.30% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GLMD
The total capital return value is set at -0.37. Equity return is now at value -37.32, with -32.78 for asset returns.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
In conclusion, Galmed Pharmaceuticals Ltd (GLMD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
